Editorial: Pursuit of a Dual-Benefit Antigout Drug: A First Look at Arhalofenate
- PMID: 26990165
- PMCID: PMC4982369
- DOI: 10.1002/art.39687
Editorial: Pursuit of a Dual-Benefit Antigout Drug: A First Look at Arhalofenate
Comment on
-
A Randomized, Double-Blind, Active- and Placebo-Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout.Arthritis Rheumatol. 2016 Aug;68(8):2027-34. doi: 10.1002/art.39684. Arthritis Rheumatol. 2016. PMID: 26989892 Free PMC article. Clinical Trial.
References
-
- Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63:3136–41. - PubMed
-
- Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F, Punzi L, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis. 2012;71:1765–70. - PubMed
-
- Lim SY, Lu N, Fisher M, Oza A, Rai SK, Menendez ME, et al. Hospitalization trends of rheumatoid arthritis and gout in the United States: a crossroad [abstract] Arthritis Rheumatol. 2015;67(Suppl 10) URL: http://acrabstracts.org/abstract/hospitalization-trends-of-rheumatoid-ar...
-
- Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11:649–62. - PubMed
-
- Neogi T. Clinical practice: gout. N Engl J Med. 2011;364:443–52. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources